Statement: All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile neutropenia.
Primary_evidence: Adverse Events 1:   Total: 2/2 (100.00%)   Febrile neutropenia * 2/2 (100.00%)   Haemorrhage NOS * 0/2 (0.00%)   Abdominal pain * 0/2 (0.00%)   Diarrhea * 0/2 (0.00%)   Melaena * 0/2 (0.00%)   Mucositis oral * 0/2 (0.00%)   Nausea * 0/2 (0.00%)   Vomiting * 0/2 (0.00%)   Catheter related infection * 0/2 (0.00%)   Infection NOS * 0/2 (0.00%)   Leukopenia * 1/2 (50.00%) Adverse Events 2:   Total: 7/29 (24.14%)   Febrile neutropenia * 1/29 (3.45%)   Haemorrhage NOS * 1/29 (3.45%)   Abdominal pain * 1/29 (3.45%)   Diarrhea * 2/29 (6.90%)   Melaena * 1/29 (3.45%)   Mucositis oral * 1/29 (3.45%)   Nausea * 1/29 (3.45%)   Vomiting * 1/29 (3.45%)   Catheter related infection * 1/29 (3.45%)   Infection NOS * 2/29 (6.90%)   Leukopenia * 0/29 (0.00%)